It seems that there is a small light in the end of the tunnel...

It seems that there is a small light in the end of the tunnel for Chemeq share holders. In today's Financial Review there is an article on Page 14 titled "Resurrected Chemeq plans broader approach to market". Below is everything that could be copied and pasted from the new Chemeq Technologies website. The text above the link dovetails with this FR news article, although interested shareholders might care to buy the paper. Bondholders are still owed $60 mill, plus another $3.5 mill they are stumping up to fund the relaunch.
wr
tu
==============

In February 2008, with the support of the Receivers and original Bondholders of the company a new licensing business was created. The new business - Chemeq Technologies Pty Ltd - is run by key management, whose fresh approach to licensing has redefined the company's strategic focus. Today Chemeq Technologies is looking to foster new long-term commercial partnerships based on each party bringing its individual strengths and experience to create a beneficial commercial outcome for all across a number of distinct applications.

Working Together
Learning from the past, Chemeq Technologies' new executive management team has undertaken a fundamental shift in strategic direction.

The company is seeking to work collaboratively with experienced, like-minded partners to share the opportunities presented by Chemyde and to take its broad commercial applications to the global marketplace. It is looking to partner with - companies with a track record of commercialization success, with a strong R&D focus, and for which this product will provide a good strategic fit.

This relationship is expected to be formalized through licensing agreements. While the scope and nature of the licenses will vary depending on the use and jurisdiction, licenses will be largely centered around:

Marketing and commercializing licenses, for more developed product opportunities (including cosmetics and animal health);
Manufacturing licenses, to secure product supply; and
Development licenses, to prospect for wider commercial uses of the technology.
===========================



http://www.chemeqtechnologies.com/
Innovation. Collaboration.
Chemeq Technologies Pty Ltd is an innovative company that has developed and patented a unique anti-microbial polymer providing the human health, personal care, specialized industrial markets, and animal health markets with a safe, effective and resistance-free alternative to antibiotics and conventional biocides.

Chemeq Technologies grew out of Chemeq Ltd, a research driven company with 17 years experience developing polyaldehydes - a revolutionary new class of anti-microbial with unique safety and efficacy profiles. The technology is protected by seven major international patents with more pending.

Anti-microbials are used in a wide range of products, including animal feeds, cosmetics, toiletries and fragrances as well as the better-known human health applications for treating infections and disinfection. However, many existing products face problems because of their limited effectiveness against certain types of microorganisms, safety issues and the development of antimicrobial resistant.

Chemeq Technologies' flagship product is the soluble, non-toxic Chemyde active ingredient. Due to its unique chemistry, Chemyde is a highly effective antimicrobial that is effective against a broad spectrum of micro-organisms, including bacteria, fungi, bacterial spores and viruses. Chemyde has potential application as a preservative, as a therapeutic or as an anti-microbial for
disinfection and sterilization uses. It is active at relatively low concentrations, broadly compatible with other ingredients and excipients, non-toxic, stable and will remain active over a wide pH range in formulation.
Today, the extensively patented Chemyde is a class-leading new technology designed to deal directly with the growing international animal and human healthcare problem presented by antibiotic resistance bacteria or "superbugs

Technology
Chemyde comes from a new class of compounds called polyaldehydes with broad spectrum activity against bacteria (gram negative and gram positive), fungi, bacterial spores, protozoa and viruses.

Polyaldehydes have a different mode of action to antibiotics and other biocides and are effective against both susceptible and resistant organisms. The product is totally synthetic with a mode of action that appears to slow or even negate the development of resistance.

Chemyde has a low oral, dermal and inhalation acute toxicity, has been shown to be non-irritant to skin, is a moderate eye irritant and has low skin sensitization potential.

Due to its properties it has wide application for therapeutic, preservative and disinfectant purposes. Broad market areas where Chemyde has potential applications are:

Animal Health, primarily GI disease and topical treatment;
Human Health, especially GI disease treatment, topical treatment and hospital disinfection and sterilization;
Personal Care, most notably as a cosmetic preservative; and
Industrial, particularly as a preservative and biocide in key industry markets such as paints, plastics, fuel, oil production inks and textiles
Chemistry
Chemyde [poly(2-propenal, 2-propenoic acid)] is an aldehydic anti-microbial polymer with a number average molecular weight (Mn) of around 2,000 Daltons.

Chemyde is synthesized via the polymerization of propenal monomer, followed by partial oxidation to introduce carboxylic acid groups to the polymer chain.

It is a pale yellow powder with a melting point above 160°C, and is soluble in aqueous buffers of pH 5 or higher. It is also soluble in alcohols and ethers, including polyethylene glycol (PEG). It can be readily incorporated into organic or aqueous formulations.

It is compatible with a wide range of compounds including: surfactants, urea, tertiary amines, glycols, hydroxyl benzoates, polyacrylamides, aldehydes, carbonates, nitrates, silicon, dyes, fragrances, proteins, carbohydrates, EDTA, mineral oils and borates.

Manufacturing process
Chemyde is a partial oxidation product of polypropenal that is in turn a product of the catalyzed polymerization of 2-propenal. Simply put, 2-propenal is converted to an intermediate product and thence to Chemyde, a soluble pale yellow powder.

While Chemeq Ltd owned and operated a pilot manufacturing plant, Chemeq Technologies' present management believes that greater economies of scale will be achieved by licensing the manufacturing process to experienced contractors.

Mode of action
Chemeq Technologies' reasearchers believe that in large part it is the aldehyde groups binding to amines and sulphides on the protein surface of the peptidoglycan layer of cell membranes that cause the cell wall to rupture, resulting in rapid microbial death.

It is the non-specific mode of action that prevents the development of resistance, and which makes it a valuable tool in the battle against so-called

superbugs.

Safety
The technology has been proven to be environmentally safe.

Independent testing of Chemyde has shown the product to be relatively non-toxic and with low potential for skin irritation, eye irritation, skin sensitization and skin absorption.

Early toxicology and environmental studies have shown very promising results on the safety of Chemyde, but a number of studies still need to be completed before full regulatory approval can be granted worldwide for widespread use in animal, human and industrial markets.

Efficacy
Research has shown that Chemyde's in-vitro anti-microbial activity is broad spectrum and effective against a wide range of bacteria, fungi and viruses. Importantly, it is effective against antibiotic-resistant organisms (including MRSA and VRE).

Repeated challenge testing has shown no development of bacterial resistance to the technology.

Specifically in the animal health market the technology has been shown to control colibacillosis in pigs; in-vitro testing has also demonstrated its effectiveness against coccidia. Further testing is required on the efficacy in chickens.

Chemyde's proven spectrum of activity against bacteria and other microbes

Aspergillus niger
P. aeruginosa
S. aureus
C. perfringens
Salmonella infantis
S. typhimurium
S. mbandaba
Listeria monocytogenes
Proteus vulgaris
S. epidermis
C. sphenoides
Legionella pneumophila
Helicobacter pylori
Giardia duodenalis
Cryptosporidium parvum
Plasmodium falciparum
Candida albicans
Malassezia pachydermatis
Mycobacterium smegmatis
Bacillus cereus
Bacillus subtilis
Herpes simplex II
Echovirus II
Influenza A
Enterococcus faecium (Vancomycin resistant - Van A and Van B)
E. coli
E. coli 0157 (resistant to Spectinomycin, Ampicillin, Lincomycin, Bacitracin, Apramycin, Tetracycline and Gentamycin

History
Intellectual Property
Chemeq's patent portfolio is made up of seven overlapping 'use', 'composition of matter' and 'manufacture of matter' patents, which cover the composition of the chemical and its manufacturing process.

The patent portfolio is particularly valuable because the inventions it covers are not limited to specific end-uses.

Patents relative to use Patent Family Description Animal Health Human Health Personal Industrial Manufacturing Expiry
1 Biocidal and Biostatic compositions 2011*
2 Chemotherapeutic compositions: treatment of GI Disease 2016
3 Compositions and methods of formulating and storing stable antmicrobial compounds 2019
4 Anti-microbial polymeric compositions 2020
5 Polymeric formulation: emulsions for topical application 2021
6 Polymeric composition: method of GI Disease treatment 2022
7 Method of manufacture of polyacrolein

=============================================== 2023




As a group, aldehydes, which include the preservatives formaldehyde and glutaraldehyde, have long been known to be anti-microbial, but their volatility and highly toxic nature has traditionally limited commercial applications.
Chemeq's research and development process discovered that by creating long-chain polymeric aldehydes, the compounds' less-desirable effects were eliminated: thanks to the large molecular size which limits absorption and tissue residues, long-chain polymeric aldehydes are non-volatile, relatively safe to handle and non-toxic. They also act differently to antibiotics and other biocides, resulting in rapid microbial death with no evidence of microbial resistance.

Keen to rapidly exploit the technology, Chemeq's discovery created great interest in the marketplace, and attracted significant investment from within Australia and overseas through an IPO and stock market listing in 1999, as well as through private and venture capital investment. A manufacturing plant (with GMP license) was built in Rockingham, WA, and the company went into production, to supply demand for the animal health product that had been registered in South Africa and subsequently New Zealand and the anticipated demand from product applications made in Australia, South America, Asia, the US and EU.

In February 2008, with the support of the Receivers and original Bondholders of the company a new licensing business was created. The new business - Chemeq Technologies Pty Ltd - is run by key management, whose fresh approach to licensing has redefined the company's strategic focus. Today Chemeq Technologies is looking to foster new long-term commercial partnerships based on each party bringing its individual strengths and experience to create a beneficial commercial outcome for all across a number of distinct applications.

===================

About Us
Chemeq Technologies Pty Ltd (CTPL) is the vehicle to license proven proprietary technology and valuable intellectual property (IP) in the form of wholly-owned patents for the process and the technology used to create its flagship product, Chemyde.

Chemyde is an innovative product from a new class of polymeric anti-microbials, which replaces antibiotics for the control of disease-causing bacteria in certain commercial animal production applications and has a broad range of other potential human and industrial applications.

Chemeq Technologies has a strong management team with expertise in licensing and development, a fresh approach and new strategic objectives. Chemeq Technologies is poised to partner with proven industry leaders under license to bring this revolutionary product to the wider market.

©2008 Chemeq Technologies

======================

Working Together
Learning from the past, Chemeq Technologies' new executive management team has undertaken a fundamental shift in strategic direction.

The company is seeking to work collaboratively with experienced, like-minded partners to share the opportunities presented by Chemyde and to take its broad commercial applications to the global marketplace. It is looking to partner with - companies with a track record of commercialization success, with a strong R&D focus, and for which this product will provide a good strategic fit.

This relationship is expected to be formalized through licensing agreements. While the scope and nature of the licenses will vary depending on the use and jurisdiction, licenses will be largely centered around:

Marketing and commercializing licenses, for more developed product opportunities (including cosmetics and animal health);
Manufacturing licenses, to secure product supply; and
Development licenses, to prospect for wider commercial uses of the technology.
Contact us for more information about working with Chemeq Technologies.

©2008 Chemeq Technologies

================

Potential Commercial Applications
Chemeq Technologies' patented polymeric antimicrobial technology targets the control of microbes in a range of markets. The inherent nature of the product is a totally synthetic biocide that, depending on dosage and time-to-kill conditions, can act as a preservative, sterilant, disinfectant, antiseptic or biocide. It has wide, utility and uniquely attractive for commercialization opportunities.

The company's globally granted and overlapping patents permit controlled access to the broad antimicrobial market, where the ongoing demand for new, safer or more effective anti-microbials is strong, and creates ongoing opportunities for the product's utilization.

Chemeq Technologies has identified a significant number of market segments across the human, industrial and agricultural sectors for commercialization opportunities.

Broadly speaking, opportunities exist in creating GI and topical treatments in both human and animal applications.

In the personal care industry, the technology can be used as a preservative, in cosmetics for example, or as a disinfectant for surface treatment.

It has a wide range of industrial applications, including being used as a preservative or biocide in paint, adhesives or drilling muds, a disinfectant of hospital surfaces and for sterilizing hospital equipment

===================

Industrial
The market for anti-microbials is significant, with the specialty anti-microbial market for industrial biocides1 expected to reach US$4 billion by 2010 with a growth rate of 4.1% per annum. Chemeq Technologies has identified significant opportunities in the following key areas:

Fuel Preservation
Electronics
Wood Treatment
Cabin Air Treatment
Disinfectant
Oil Recovery
Plastics
Inks
Paper
Textiles
Water Towers
Pools
Adhesives
Mud Drilling
===============================
Human Health
The pharmaceutical market for anti-microbials is valued at US$33.25 billion for human health applications1 and US$1 billion in the personal care market2. Some key opportunities include:

Medical Applications
Equipment Sterilization
Stomach Ulcers
Disinfectant
Acne Treatment
Gloves
HIV Treatment
Dressings
Wound creams
Hand wash
Catheters
Personal Care Applications
Cosmetic preservative
Antidandruff
Antibacterial Wipes
Toothpaste
Athlete's Foot

Sources:
Industrial Antimicrobial Agents - Applications and Markets in Various Regions 2000-2005-2010 (Frost and Sullivan)
The Global Antibacterial market - 2007 (Arrowhead
=============================

Agricultural
Currently, the antibiotic feed market1 for animal health is valued at US$1.995 billion, a figure that is expected to rise with changing international agricultural practices and the increase in prevalence of antibiotic-resistant superbugs.

Animal Health
Aquatic
Mastitis
Companion Animals
GI Treatment in Pigs and Poultry
Crop Protection
Seed treatment
Fruit Treatment
Sources:
International Federation of Animal Health - www.ifahsec.org